|1.||Dalessandro, Marybeth: 3 articles (12/2014 - 09/2008)|
|2.||Scangarella-Oman, Nicole E: 2 articles (12/2014 - 04/2009)|
|3.||Li, Gang: 2 articles (12/2014 - 02/2009)|
|4.||Shawar, Ribhi M: 2 articles (04/2009 - 09/2008)|
|5.||Twynholm, Monique: 2 articles (02/2009 - 01/2007)|
|6.||Shawar, Ribhi: 2 articles (02/2009 - 01/2007)|
|7.||Parish, Lawrence Charles: 2 articles (02/2008 - 12/2006)|
|8.||Keam, Susan J: 2 articles (01/2008 - 01/2008)|
|9.||Yang, Lily P H: 2 articles (01/2008 - 01/2008)|
|10.||Tanus, Tonny: 1 article (12/2014)|
01/01/2007 - "Retapamulin is a highly effective and convenient new treatment option for impetigo, with efficacy against isolates resistant to existing therapies."
05/01/2008 - "This study shows that topical retapamulin is effective and safe in the treatment of primary impetigo, offering a new treatment option."
05/01/2008 - "Efficacy and safety of retapamulin ointment as treatment of impetigo: randomized double-blind multicentre placebo-controlled trial."
01/01/2014 - "Ozenoxacin 1% cream in the treatment of impetigo: a multicenter, randomized, placebo- and retapamulin-controlled clinical trial."
03/01/2009 - "Recently retapamulin has been released as a new antibiotic for topical use in impetigo contagiosa. "
02/01/2008 - "In clinical efficacy trials involving pediatric and adult patients who received retapamulin twice daily for five days, retapamulin was highly effective in the treatment of impetigo, secondarily infected traumatic lesions and secondarily infected dermatitis. "
07/01/2014 - "The authors hypothesized that retapamulin 1% ointment and clobetasol propionate 0.05% foam would decrease disease severity in subjects with hand/foot dermatitis and provide a higher clearance of Staphylococcus aureus colonization, when compared to vehicle (placebo) ointment and clobetasol propionate 0.05% foam. "
07/01/2014 - "At Day 15, retapamulin 1% ointment with clobetasol propionate 0.05% foam was more efficacious than vehicle ointment and clobetasol propionate 0.05% foam for disease improvement and Staphylococcus aureus clearance in adult subjects with hand/foot dermatitis."
07/01/2014 - "Adult subjects with moderate to very severe hand/foot dermatitis had twice-daily topical application of clobetasol propionate 0.05% foam to hands/feet for 14 days and were randomized to apply either retapamulin 1% ointment or vehicle ointment twice daily to hands/feet and nares for five days. "
07/01/2014 - "Retapamulin 1% Ointment and Clobetasol Propionate 0.05% Foam is More Efficacious than Vehicle Ointment and Clobetasol 0.05% Propionate Foam in the Treatment of Hand/Foot Dermatitis: A Single Center, Randomized, Double-blind Study."
12/01/2014 - "To evaluate the clinical and bacteriological efficacy of topical retapamulin ointment 1% versus oral linezolid in the treatment of patients with secondarily infected traumatic lesions (SITLs; excluding abscesses) or impetigo due to methicillin-resistant Staphylococcus aureus (MRSA). "
01/01/2008 - "In patients with secondarily infected traumatic lesions, treatment with retapamulin was noninferior to that with oral cephalexin, although the efficacy of retapamulin was reduced in patients with MRSA infections or superficial abscesses. "
01/01/2008 - "In patients with secondarily infected traumatic lesions, treatment with retapamulin was noninferior to that with oral cefalexin, although the efficacy of retapamulin was reduced in patients with MRSA infections or superficial abscesses. "
01/01/2008 - "In the EU, retapamulin is indicated for use in patients with impetigo or with infected small lacerations, abrasions, or sutured wounds (without abscesses); in the US, it is indicated for use in patients with impetigo. "
01/01/2008 - "In the EU, retapamulin is indicated for use in patients with impetigo or with infected small lacerations, abrasions or sutured wounds (without abscesses); in the US, it is indicated for use in patients with impetigo. "
09/01/2008 - "Isolates were recovered from patients with uncomplicated skin infections in 10 different countries during five phase III global clinical trials of retapamulin, a new topical antibiotic agent. "
02/01/2008 - "In preclinical studies, retapamulin demonstrated pronounced in vitro activity against staphylococcal, streptococcal and anaerobic Gram-positive clinical isolates associated with skin and skin structure infections. "
07/01/2012 - "Twice-daily application of retapamulin 1% produced a mean 8.1-point reduction from baseline in the mean Skin Infection Rating Scale score. "
10/01/2009 - "In 2007, Retapamulin, as the first in a new class of topical antibacterial in the nearly two decades, was approved for use in human skin infections. "
02/01/2008 - "Retapamulin: a new topical antibiotic for the treatment of uncomplicated skin infections."
|5.||Atopic Dermatitis (Atopic Eczema)
07/01/2012 - "Given its efficacy and good tolerability in this pilot study, retapamulin 1% ointment should be further evaluated as a treatment for infected atopic dermatitis. "
07/01/2012 - "Efficacy and tolerability of retapamulin 1% ointment for the treatment of infected atopic dermatitis: a pilot study."
01/01/2010 - "Retapamulin: what is the role of this topical antimicrobial in the treatment of bacterial infections in atopic dermatitis?"
07/01/2012 - "Retapamulin 1% is effective for the treatment of atopic dermatitis infected with S aureus, and demonstrates efficacy against both methicillin-susceptible and methicillin-resistant strains. "
07/01/2012 - "A single-center, open-label pilot study was conducted to investigate the efficacy and safety of retapamulin 1% (Altabax, Stiefel/ GlaxoSmithKline) ointment for the treatment of secondarily infected atopic dermatitis in subjects aged 9 months to 98 years old (n=29). "
|3.||Fusidic Acid (Fucithalmic)
|5.||Clobetasol (Clobetasol Propionate)